AZ saw double-digit revenue increase in Q2

Friday 29 July 2022

United Kingdom

AstraZeneca Plc reported a 31% increase in total revenue to $10.8 billion for the second quarter, driven by its cardiovascular and oncology medicines as well as income from Alexion Pharmaceuticals, a developer of drugs for rare diseases which it acquired in July 2021. The second quarter revenue figure includes three drugs with more than $1 billion in sales: Tagrisso for lung cancer; Farxiga, for diabetes, heart failure and kidney disease; and Alexion’s Soliris for myasthenia gravis and three other rare diseases.